<DOC>
	<DOCNO>NCT02362412</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics switch FK949E ( sustained-release quetiapine ) 50-mg 150-mg tablet tablet equivalent total daily dose bipolar disorder patient major depressive episode .</brief_summary>
	<brief_title>Study Evaluate Effects Switching Different Strength Forms FK949E Bipolar Disorder Patients With Major Depressive Episodes</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnosis bipolar I II disorder specify Diagnostic Statistical Manual Mental Disorders , 4th edition , Text Revision ( DSMIVTR ) , major depressive episode . Able participate study understand compliance subject requirement study investigator 's subinvestigator 's opinion . Concurrent previous history DSMIVTR Axis I disorder , except bipolar disorder , within last 6 month inform consent . Concurrence DSMIVTR Axis II disorder consider greatly affect patient 's current mental status . The Young Mania Rating Scale ( YMRS ) total score 13 point . Nine mood episode within last 12 month inform consent . Lack response least 6week treatment least 2 antidepressant current major depressive episode investigator 's subinvestigator 's opinion . The current major depressive episode persist less 4 week inform consent . History substance dependence ( caffeine nicotine ) alcohol abuse dependence . Treatment depot antipsychotic within last 49 day start pretreatment observation period . Unable suspend antipsychotic antidepressant start pretreatment observation period . Treatment one follow three drug , mood stabilizer ( lithium carbonate and/or sodium valproate ) lamotrigine , drug , except one either drug , suspend start pretreatment observation period . Unable suspend antiepileptic ( except lamotrigine sodium valproate ) , antianxiety agent , hypnotic , sedative , psychostimulants , antiparkinsonian agent , cerebral ameliorators , antidementia agent , anorectic , except specify conditionallyallowed concomitant drug , 7 day start pretreatment observation period . Unable suspend CYP3A4 inhibitor inducer , monoamine oxidase ( MAO ) inhibitor 7 day start pretreatment observation period . Electroconvulsive therapy within last 83 day start pretreatment observation period . A possible need psychotherapy study period ( unless therapy commence least 83 day start pretreatment observation period ) . The Hamilton Depression Rating Scale ( HAMD17 ) suicide score 3 point , history suicide attempt within last 6 month inform consent , risk suicide investigator 's subinvestigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>major depressive episode</keyword>
	<keyword>FK949E</keyword>
	<keyword>quetiapine</keyword>
	<keyword>bipolar depression</keyword>
	<keyword>bipolar disorder</keyword>
</DOC>